Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of “Hold” by Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have been assigned a consensus recommendation of “Hold” from the twenty ratings firms that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $127.1765.

Several analysts have issued reports on ILMN shares. Evercore ISI reiterated an “outperform” rating and issued a $155.00 target price on shares of Illumina in a research note on Monday, January 5th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Illumina in a report on Monday, December 29th. Barclays increased their price objective on Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a research report on Monday, December 15th. Canaccord Genuity Group upped their target price on Illumina from $130.00 to $150.00 and gave the stock a “hold” rating in a research note on Monday. Finally, Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a report on Saturday, January 17th.

Insider Activity at Illumina

In other Illumina news, insider Scott M. Davies sold 323 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the transaction, the insider owned 17,887 shares of the company’s stock, valued at $2,434,241.83. The trade was a 1.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Scott Gottlieb purchased 500 shares of the firm’s stock in a transaction dated Monday, November 3rd. The stock was bought at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the acquisition, the director directly owned 12,523 shares in the company, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On Illumina

Several hedge funds have recently added to or reduced their stakes in the company. Next Capital Management LLC purchased a new stake in shares of Illumina during the second quarter worth about $341,000. CWM LLC increased its holdings in Illumina by 112.9% during the 2nd quarter. CWM LLC now owns 76,711 shares of the life sciences company’s stock valued at $7,319,000 after purchasing an additional 40,676 shares during the period. Generali Asset Management SPA SGR raised its position in Illumina by 51.6% during the 3rd quarter. Generali Asset Management SPA SGR now owns 22,249 shares of the life sciences company’s stock valued at $2,113,000 after purchasing an additional 7,574 shares during the last quarter. Andra AP fonden raised its position in Illumina by 426.3% during the 2nd quarter. Andra AP fonden now owns 102,491 shares of the life sciences company’s stock valued at $9,779,000 after purchasing an additional 83,017 shares during the last quarter. Finally, Aaron Wealth Advisors LLC lifted its holdings in Illumina by 342.6% in the 3rd quarter. Aaron Wealth Advisors LLC now owns 10,476 shares of the life sciences company’s stock worth $995,000 after buying an additional 8,109 shares during the period. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of ILMN opened at $149.69 on Friday. Illumina has a 52-week low of $68.70 and a 52-week high of $155.53. The stock’s 50-day simple moving average is $137.67 and its 200 day simple moving average is $114.58. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43. The stock has a market capitalization of $22.87 billion, a price-to-earnings ratio of 33.56, a price-to-earnings-growth ratio of 2.48 and a beta of 1.41.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the previous year, the firm earned $1.14 EPS. The company’s quarterly revenue was up .4% compared to the same quarter last year. Research analysts forecast that Illumina will post 4.51 EPS for the current fiscal year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.